

PATENT / DOCKET NO.: 6643R2
CUSTOMER NO.: 27752

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

James B. Camden, et al.

Serial No.: 09/676,034

Filed: September 29, 2000

For: Compounds and Methods for Use
Thereof In the Treatment of Cancer
(as amended)§
§
§
§
§
§
§
§
§
§

Examiner: Delacroix Muirheid, C.

Group Art Unit: 1614

RECEIVED
CENTRAL FAX CENTER

OCT 31 2003

OFFICIAL

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT; RESPONSE TO OFFICE ACTION
MAILED MARCH 21, 2003

The present paper is submitted as a complete response to the Official Action mailed March 21, 2003 having a shortened statutory period of response of three months, to June 21, 2003. The present paper is timely filed since this paper is being filed prior to or on the three-month date; however, should an extension of time be required, this paper is such a request. No fees are believed due for the filing of the present document, however, should any fees be due, the Commissioner is authorized to deduct said fees under 37 C.F.R. §§ 1.16 to 1.21 from Haynes and Boone Deposit Account No. 08-1394.

AMENDMENT TO THE SPECIFICATION

Amend the title as follows: Compounds and Methods for Use Thereof In the Treatment of Cancer or Viral Infections.

Amend the paragraph at page 17, line 28 as follows: ~~Taxol~~ TAXOL® (paclitaxel) is a preferred chemotherapeutic agent.

Amend the paragraph at page 22, line 13 as follows: Further potentiators include, but are not limited to, propionic acid, salts thereof, or esters thereof; antioxidant vitamins such as vitamins A, C, E, or beta-carotene; abacavir; AL-721 (lipid mixture); amprenavir; Amphotericin B methyl ester; ~~Ampligen~~ AMPLIGEN® (mismatched RNA); anti-AIDS antibody; anti-human interferon- α antibody; anti-AIDS antibody; ascorbic acid and derivatives thereof; AS-101 (heavy metal based immunostimulant); azidothymidine; β -interferon; Bropiramine; butylated hydroxytoluene; Ciamexon, Cimetidine; CL-246,738, colony stimulating factors, including GM-CSF; Creme Pharmatex (benzalkonium chloride); CS-82 (5-unsubstituted derivative of Zidovudine); Cyclosporin; D-penicillamine (3-mercapto-D-valine); delavirdine; dextran sulphate; dinitrochlorobenzene; efavirenz; erythropoietin; Foscarnet (trisodium phosphonoformate); fusidic acid; ganciclovir; glucan; glycyrrhizin, HPA-23 (ammonium-21-tungsto-9-antimonate); human immunodeficiency virus antiviral; hyperimmune gamma-globulin, IMREG®-1, IMREG®-2, low molecular weight subfractions derived from human leukocyte dialysates; indinavir; interferon- α ; interferon-gamma; interleukin-1 or interleukin-2; isoprinosine; Krestin; LC-9018; lamivudine; lentilart; LF-1695; methionine-enkephalin; ~~Minophagen~~ MINOPHAGEN® C (glycyrrhizin); muramyl tripeptide; naltrexone; nelfinavir; Neutropin; nevirapine; Nonoxinol; ~~Ornidyl~~ ORNIDYL® (eflornithine); non-nucleoside inhibitors of reverse transcriptase; nucleoside analogues (ddA, ddC, ddI, ddT, ddG, AZT, and the like); pentamidine isethionate; Phenytoin; polymannosylacetate; Peptide T® (octapeptide sequence); protease inhibitors; Ribavirin; Rifabutin (ansamycin); ritonavir; RNA immunomodulator; rsT4 (recombinant soluble T4); saquinavir; shosaikoto and ginseng; SK-818 (germanium-derived antiviral); sodium diethylthiocarbamate; stavudine; stearic acid derivative; suramin and analogues thereof; thymic humoral factor; TP-5; Thymosin fraction 5 and Thymosin 1; Thymostimulin; TNF (tumor necrosis factor), vitamin B preparations; Trimetrexate; UA001; α -interferon or acyclovir, for example.